173 related articles for article (PubMed ID: 36207935)
1. [Proteomic-driven precision medicine research in hepatocellular carcinoma].
Jiang Y; He FC
Zhonghua Gan Zang Bing Za Zhi; 2022 Aug; 30(8):797-802. PubMed ID: 36207935
[TBL] [Abstract][Full Text] [Related]
2. The application of proteomics in different aspects of hepatocellular carcinoma research.
Xing X; Liang D; Huang Y; Zeng Y; Han X; Liu X; Liu J
J Proteomics; 2016 Aug; 145():70-80. PubMed ID: 27072111
[TBL] [Abstract][Full Text] [Related]
3. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
4. Proteomics for hepatocellular carcinoma marker discovery.
Chignard N; Beretta L
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S120-5. PubMed ID: 15508075
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma: Role of Pathology in the Era of Precision Medicine.
Vyas M; Zhang X
Clin Liver Dis; 2020 Nov; 24(4):591-610. PubMed ID: 33012447
[TBL] [Abstract][Full Text] [Related]
6. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
[TBL] [Abstract][Full Text] [Related]
7. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma.
Nie W; Yan L; Lee YH; Guha C; Kurland IJ; Lu H
Mass Spectrom Rev; 2016; 35(3):331-49. PubMed ID: 24890331
[TBL] [Abstract][Full Text] [Related]
8. Proteomic investigations into hypertension: what's new and how might it affect clinical practice?
Corbacho-Alonso N; Rodríguez-Sánchez E; Martin-Rojas T; Mouriño-Alvarez L; Sastre-Oliva T; Hernandez-Fernandez G; Padial LR; Ruilope LM; Ruiz-Hurtado G; Barderas MG
Expert Rev Proteomics; 2019 Jul; 16(7):583-591. PubMed ID: 31195841
[No Abstract] [Full Text] [Related]
9. The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine.
Doll S; Gnad F; Mann M
Proteomics Clin Appl; 2019 Mar; 13(2):e1800113. PubMed ID: 30790462
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of laser capture microdissected focal lesions in a rat model of progenitor marker-positive hepatocellular carcinoma.
Adebayo Michael AO; Ahsan N; Zabala V; Francois-Vaughan H; Post S; Brilliant KE; Salomon AR; Sanders JA; Gruppuso PA
Oncotarget; 2017 Apr; 8(16):26041-26056. PubMed ID: 28199961
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist.
Kim J; Jin P; Yang W; Kim WJ
Investig Clin Urol; 2020 Nov; 61(6):539-554. PubMed ID: 33135400
[TBL] [Abstract][Full Text] [Related]
12. Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities.
Padhye BD; Nawaz U; Hains PG; Reddel RR; Robinson PJ; Zhong Q; Poulos RC
Pediatr Blood Cancer; 2024 Jun; 71(6):e30980. PubMed ID: 38556739
[TBL] [Abstract][Full Text] [Related]
13. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.
Jiang Y; Sun A; Zhao Y; Ying W; Sun H; Yang X; Xing B; Sun W; Ren L; Hu B; Li C; Zhang L; Qin G; Zhang M; Chen N; Zhang M; Huang Y; Zhou J; Zhao Y; Liu M; Zhu X; Qiu Y; Sun Y; Huang C; Yan M; Wang M; Liu W; Tian F; Xu H; Zhou J; Wu Z; Shi T; Zhu W; Qin J; Xie L; Fan J; Qian X; He F;
Nature; 2019 Mar; 567(7747):257-261. PubMed ID: 30814741
[TBL] [Abstract][Full Text] [Related]
14. Positional proteomics in the era of the human proteome project on the doorstep of precision medicine.
Eckhard U; Marino G; Butler GS; Overall CM
Biochimie; 2016 Mar; 122():110-8. PubMed ID: 26542287
[TBL] [Abstract][Full Text] [Related]
15. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
16. Proteomics and personalized medicine: a focus on kidney disease.
Siwy J; Mischak H; Zürbig P
Expert Rev Proteomics; 2019 Sep; 16(9):773-782. PubMed ID: 31441341
[No Abstract] [Full Text] [Related]
17. Proteomic Approaches to Enable Point-of-Care Testing and Personalized Medicine for Psychiatric Disorders.
Guest FL; Guest PC
Adv Exp Med Biol; 2017; 974():363-370. PubMed ID: 28353256
[TBL] [Abstract][Full Text] [Related]
18. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry analysis of glycoprotein biomarkers in human blood of hepatocellular carcinoma.
Kim KH; Kim JY; Yoo JS
Expert Rev Proteomics; 2019 Jul; 16(7):553-568. PubMed ID: 31145639
[No Abstract] [Full Text] [Related]
20. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
Kim H; Yu SJ; Yeo I; Cho YY; Lee DH; Cho Y; Cho EJ; Lee JH; Kim YJ; Lee S; Jun J; Park T; Yoon JH; Kim Y
Mol Cell Proteomics; 2017 Jul; 16(7):1312-1323. PubMed ID: 28550167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
